Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

New diagnosis of Barrett's esophagus changes insurance status

A diagnosis of Barrett's esophagus more than doubles life insurance premiums, and impacts the availability of health insurance, reports March's issue of The American Journal of Gastroenterology.

News image

fiogf49gjkf04

Barrett's esophagus is associated with an increased risk of adenocarcinoma of the esophagus.

Despite this increased risk, most cohort studies demonstrate that the mean life expectancy of subjects with Barrett's esophagus is no different than age-matched controls.

The indirect costs associated with a diagnosis of Barrett's esophagus are unclear.

Dr Shaheen and colleagues assessed the effect of a diagnosis of Barrett's esophagus on insurance premiums.

The researchers assessed 20 national life insurance companies (10 in southern California, 10 in North Carolina) to determine the effect of a diagnosis of Barrett's esophagus on life insurance premiums.

The investigators’ base case in Los Angeles was a 36 year old female nonsmoker, and in North Carolina, a 43 year old Caucasian male nonsmoker, both in excellent health except for a diagnosis of prevalent Barrett's esophagus with no dysplasia.

The investigative team then requested a policy of 20 year guaranteed term life insurance in the amount of $1,000,000.

Companies refused to provide health insurance to the individual with Barrett's esophagus or requested further medical review
The American Journal of Gastroenterology

Companies were asked for their best price exclusive of the Barrett's esophagus, and also their best price when considering Barrett's esophagus as a preexisting condition.

The researchers subsequently sent a physician's letter explaining Barrett's esophagus and providing data substantiating a normal life expectancy in the condition to those companies not offering the "preferred" rates.

The team also asked companies for health insurance quotes, including premiums and deductibles, inclusive and exclusive of the diagnosis of Barrett's esophagus.

The investigators contacted 29 national insurance companies and for the 43 year old man with no Barrett's esophagus, the yearly "preferred" premium for life insurance averaged $1,255.

The mean cost of the policies offered to the same individual with Barrett's esophagus as a preexisting condition was $2,731.

The researchers noted that for the 36 year old female the base rate exclusive of Barrett's esophagus was $517, with a range of $472 - $551.

After inclusion of the diagnosis of Barrett's esophagus, the mean rate rose by 177%, to $1,434, with a range of $1,144 - $1,896.

The investigators reported that companies either refused to provide health insurance to the individual with Barrett's esophagus or would not provide a quote without review of the medical record.

The team observed that none of the insurance companies changed their quoted rates after receiving the letter written by the physician on behalf of the individual.

Dr Shaheen concludes, “Despite the preponderance of data demonstrating a normal life expectancy associated with the condition, a diagnosis of Barrett's esophagus more than doubles life insurance premiums, and impacts the availability of health insurance.”

“Further steps to educate insurance companies about the risks associated with Barrett's esophagus are warranted, and patients should understand this additional "risk" of endoscopic screening for Barrett's esophagus.”

“There are significant indirect costs associated with a diagnosis of Barrett's esophagus.”

The American Journal of Gastroenterology 2005: 100(3): 577
09 March 2005

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us